Radiation beads for recurrent glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new way to deliver radiation directly to the tumor using tiny beads placed during a procedure. It is for people whose glioblastoma has come back after standard treatments, and it aims to slow or stop tumor growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- Your glioblastoma has come back after standard treatment (surgery, radiation, and chemotherapy).
- You have not had more than one previous course of brain radiation.
- Your tumor is in a part of the brain that allows safe placement of the beads.
- Your overall health is good enough to undergo the procedure and follow-up.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests whether a device called TheraSphere is safe when delivered into the brain to treat recurrent glioblastoma. It may help patients by trying a targeted treatment approach, while doctors carefully monitor side effects and safety.
This trial tests a treatment that delivers tiny radioactive beads directly to the blood vessels feeding a recurrent brain tumor, aiming to kill cancer cells while sparing healthy tissue. It is for people whose glioblastoma has returned after standard treatments like radiation and chemotherapy.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This study tests a combination of two drugs for people with glioblastoma that has come back after treatment with bevacizumab (a drug that targets blood vessel growth). The goal is to see if this new combination can shrink the tumor or slow its growth.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.